IDEXX Laboratories (IDXX) recently extended its Cancer Dx Panel to veterinary practices in the United Kingdom, giving investors fresh product news to weigh alongside upcoming first quarter 2026 results and the existing companion animal diagnostics business.
See our latest analysis for IDEXX Laboratories.
Despite the Cancer Dx expansion and the upcoming Q1 2026 earnings release, IDEXX Laboratories’ recent 1 month share price return of 6.25% and 3 month share price return of 21.08% contrast with a 1 year total shareholder return of 44.01%. This suggests momentum has cooled after a strong run.
If this kind of diagnostics story has your attention, it can be useful to see what else is gaining interest through the 31 healthcare AI stocks
With a recent 3 month share price decline of 21.08% against a 1 year total return of 44.01%, the key question now is whether IDEXX is resetting to a more attractive entry point or if the market is already banking on future performance.
Most Popular Narrative: 25% Undervalued
With IDEXX Laboratories last closing at $563 and the most followed narrative pointing to a fair value of about $750, the gap between price and modeled worth is significant enough to catch attention.
Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.
Curious what kind of revenue growth, margin profile, and future P/E multiple are baked into that fair value? The narrative focuses on recurring diagnostics and a premium earnings multiple to explain the gap between price and estimated worth.
Result: Fair Value of $750 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, softer U.S. clinical visit trends and the dependence on rapid instrument placements leave this upbeat diagnostics narrative exposed if demand or adoption slows.
Find out about the key risks to this IDEXX Laboratories narrative.
Another View: High Multiple, Different Message
While the narrative fair value of $750 points to upside, the current P/E of 42.3x sits well above the US Medical Equipment industry at 26.3x, the peer average at 26.4x, and the fair ratio of 28.5x. That premium suggests less room for error if growth or margins soften. The key question is which story you trust more: the modelled upside or the rich multiple.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals on value and growth running through this story, it makes sense to check the underlying data and decide quickly where you stand, then weigh up the 3 key rewards and 2 important warning signs.
Looking for more investment ideas?
If IDEXX has sharpened your focus, do not stop here. Broaden your watchlist with other focused stock ideas that might suit different goals and risk levels.
- Target potential mispricing by checking out quality companies that appear overlooked through the 58 high quality undervalued stocks.
- Build a steadier income stream by reviewing companies with stronger yields through the 11 dividend fortresses.
- Prioritize resilience by scanning companies with sturdier finances using the solid balance sheet and fundamentals stocks screener (41 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com